5 stories mentioning HKG:2096Updated 9d ago
Every FINWIRES story that references HKG:2096, newest first.
Simcere Pharmaceutical (HKG:2096) obtained approval from China's National Medical Products Administration to conduct clinical trials of SIM0689, according to a Friday Hong Kong bourse filing.The company intends to evaluate the PD-1/VEGF bispecific antibody in patients with advanced solid tumors.
Simcere Pharmaceutical (HKG:2096) entered into an exclusive promotion service agreement with PrimeGenX Therapeutics for Pumecitinib Gel, a Monday Hong Kong bourse filing said.Under the agreement, Simcere obtained exclusive promotion rights for the drug's dermatology indications in mainland China, Hong Kong, and Macau.Pumecitinib Gel is described as the "world's first" JAK inhibitor gel for atopic dermatitis and is also being developed for additional dermatology indications, including atopic dermatitis in children aged 2 to 11, prurigo nodularis, and non-segmental vitiligo, according to the filing.
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
Simcere Pharmaceutical's (HKG:2096) resubmitted new drug application for Rademikibart was accepted by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The acceptance is for the use of the drug, which was jointly developed by the firm and Connect Biopharma Hong Kong, for the treatment of atopic dermatitis in adults and adolescents.
Simcere Pharmaceutical (HKG:2096) posted profit attributable to equity shareholders of 1.34 billion yuan for 2025, up 86% from 722 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.Shares of the pharmaceutical firm were down 1% in recent trade.Earnings per share came in at 0.54 yuan from 0.29 yuan a year earlier.Revenue rose 16.5% to 7.73 billion yuan from 6.64 billion yuan in 2024.
